Corrigendum to “Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells”
First published: 02 December 2018
In the article titled “Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells” [1], there was an error in Figure 3(d), where the blots for SHP-2 and Tubulin were duplicated by mistake. Some of the underlying blots are available in the Supplementary Materials (available here). The figure should be corrected as below.
Figure 3 (a)
Cryptotanshinone inactivates STAT3, but not STAT5, in K562 cells. (a) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h (left) or 20 μM for 0, 6, 12, or 24 h (right). Cell lysates were prepared and subjected to Western blotting for phospho-STAT3 and phospho-STAT5. (b) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h. Gel shift mobility assay was performed to determine the STAT3/DNA binding activity. (c) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h. Western blotting was performed to detect phosphorylation of JAK2. (d) Cells were treated with 20 μM cryptotanshinone for 0, 3, 6, 12, 24, or 36 h. Western blotting was conducted to determine the expression of SHP-1 and SHP-2.
Figure 3 (b)
Cryptotanshinone inactivates STAT3, but not STAT5, in K562 cells. (a) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h (left) or 20 μM for 0, 6, 12, or 24 h (right). Cell lysates were prepared and subjected to Western blotting for phospho-STAT3 and phospho-STAT5. (b) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h. Gel shift mobility assay was performed to determine the STAT3/DNA binding activity. (c) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h. Western blotting was performed to detect phosphorylation of JAK2. (d) Cells were treated with 20 μM cryptotanshinone for 0, 3, 6, 12, 24, or 36 h. Western blotting was conducted to determine the expression of SHP-1 and SHP-2.
Figure 3 (c)
Cryptotanshinone inactivates STAT3, but not STAT5, in K562 cells. (a) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h (left) or 20 μM for 0, 6, 12, or 24 h (right). Cell lysates were prepared and subjected to Western blotting for phospho-STAT3 and phospho-STAT5. (b) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h. Gel shift mobility assay was performed to determine the STAT3/DNA binding activity. (c) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h. Western blotting was performed to detect phosphorylation of JAK2. (d) Cells were treated with 20 μM cryptotanshinone for 0, 3, 6, 12, 24, or 36 h. Western blotting was conducted to determine the expression of SHP-1 and SHP-2.
Figure 3 (d)
Cryptotanshinone inactivates STAT3, but not STAT5, in K562 cells. (a) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h (left) or 20 μM for 0, 6, 12, or 24 h (right). Cell lysates were prepared and subjected to Western blotting for phospho-STAT3 and phospho-STAT5. (b) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h. Gel shift mobility assay was performed to determine the STAT3/DNA binding activity. (c) Cells were treated with cryptotanshinone (0, 10, or 20 μM) for 24 h. Western blotting was performed to detect phosphorylation of JAK2. (d) Cells were treated with 20 μM cryptotanshinone for 0, 3, 6, 12, 24, or 36 h. Western blotting was conducted to determine the expression of SHP-1 and SHP-2.
